Manufactured Object
Johnson & Johnson Announces $55 Billion Investment in U.S. Manufacturing and Innovation
This major investment demonstrates J&J’s commitment to expanding its U.S. manufacturing and innovation capabilities, with potential benefits for job creation and the domestic pharmaceutical industry. The announcement aligns with broader trends of increased U.S. manufacturing investment by large corporations in recent years.
Adaptimmune, after bringing cell therapy to market, questions viability and defunds 2 preclinical programs
Adaptimmune, Tecelra, Viable, Market, Solid Neoplasm, cellular targeting
A closer look at pharmas top patent losses in 2025
Legal patent, Expiration, function, Market, Indication of (contextual qualifier), competition, Impact food supplement, Sales – occupational activity, Bayer, 2025, patent cliff, Regeneron, 2023
Drugmakers renew concerns over UK’s attractiveness for investment
Investments, UK, UK ‘s, concerns, Industry, attractiveness
Opko, Entera share ownership of first oral GLP-1/glucagon agonist set to enter clinic
entera, GLP-1/glucagon, first, Oral cavity, OPKO, Ownership, Entera
Sutro discards CEO, 50% of staff, sole clinical-stage ADC and manufacturing site to save cash
Sutro, therapeutic autologous dendritic cells, Changing, CEO, Cash
J&J, Legend to invest $150M in Belgium cell therapy facility as new Carvykti rival looms
Carvykti, Johnson and Johnson, Investments, J&J, Facility (object), Multiple Myeloma, production, competition
Corrected: Merck opens billion-dollar US facility to make Gardasil
Merck, Gardasil, Facility (object), Vaccines, Merck ‘s, United States